Peritoneal Metastases from Gastrointestinal Cancer. [Review] (Record no. 3530)

MARC details
000 -LEADER
fixed length control field 02201nam a22003377a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190724s20182018 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1523-3790
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/s11912-018-0703-0 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/s11912-018-0703-0 [pii]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 29884974
245 ## - TITLE STATEMENT
Title Peritoneal Metastases from Gastrointestinal Cancer. [Review]
251 ## - Source
Source Current Oncology Reports. 20(8):62, 2018 06 08.
252 ## - Abbreviated Source
Abbreviated source Curr Oncol Rep. 20(8):62, 2018 06 08.
253 ## - Journal Name
Journal name Current oncology reports
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2018
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2018
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status epublish
266 ## - Date added to catalog
Date added to catalog 2018-07-06
520 ## - SUMMARY, ETC.
Abstract PURPOSE OF REVIEW: Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation vs. an aggressive approach using cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy must be made. The perioperative chemotherapy may be hyperthermic intraperitoneal chemotherapy (HIPEC) administered in the operating room or early postoperative intraperitoneal chemotherapy (EPIC) administered in the first 4 or 5 postoperative days.
520 ## - SUMMARY, ETC.
Abstract RECENT FINDINGS: This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, the clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur. Peritoneal metastases should always be considered for treatment or prevention.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution Washington Cancer Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Review
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Sugarbaker, Paul H
790 ## - Authors
All authors Sugarbaker PH
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1007/s11912-018-0703-0">https://dx.doi.org/10.1007/s11912-018-0703-0</a>
Public note https://dx.doi.org/10.1007/s11912-018-0703-0
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 07/06/2018   29884974 29884974 07/06/2018 07/06/2018 Journal Article

Powered by Koha